Regulatory note: Injectable/IV NAD+ is not FDA-approved (or approved by any major regulator) for energy, metabolic or longevity uses
Conquering Menopause and Perimenopause Weight Gain Perhaps the most challenging period for weight control is the transition into menopause
Better Energy and Mobility As patients lose weight, they often gain energy and mobility, making it easier to continue an active lifestyle
Animals were randomly assigned to treatment groups using a simple randomization approach
In controlled Phase 3 trials of HUMIRA (40 mg SC every other week) in subjects with RA, PsA, and AS with control period duration ranging from 4 to 104 weeks, ALT elevations 3 x ULN occurred in 3.5% of HUMIRA-treated subjects and 1.5% of control-treated subjects
The inflammatory state caused by sleep deprivation has direct pathogenic implications for metabolic parameters and cardiovascular outcomes